Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: November 2015

25 - Management of cancer of the ovary

Summary

Introduction

Ovarian cancer is the fifth most common cancer in women and the second most common gynaecological cancer, but the most common cause of death from gynaecological malignancy in the Western world. Epithelial ovarian cancer, fallopian tube cancer and peritoneal cancer share similar characteristics and behaviour and are treated in the same way. Ovarian cancer has been named a ‘silent killer’ because of its lack of symptoms during early stages. Around 90% of ovarian cancers arise from the epithelium. Two-thirds of patients present with stage III or IV disease, with increasing abdominal symptoms including ascites. Treatment typically depends on a combination of surgery and chemotherapy. In recent years there has been interest in the role of biological treatments, particularly the angiogenesis inhibitor, bevacizumab. Over the past 40 years there has been a modest increase in the survival from ovarian cancer in the UK, attributable primarily to the use of platinum-based chemotherapy, and around 40% of patients are expected to survive for 5 years or more.

Types of tumour affecting the ovary

The WHO classification of tumours of the ovary defines broad categories of ovarian tumours (WHO classification, 2003):

  1. • surface epithelial–stromal tumours;

  2. • sex cord–stromal tumours;

  3. • germ cell tumours;

  4. • tumours of the rete ovarii;

  5. • miscellaneous tumours;

  6. • lymphomas and haematopoietic tumours;

  7. • secondary tumours.

Surface epithelial–stromal tumours are classified as benign, borderline or malignant. The subtypes are serous, mucinous, endometrioid, malignant mixed müllerian tumour (carcinosarcoma), clear cell, transitional cell, squamous cell, mixed and undifferentiated or unclassified.

Sex cord–stromal tumours are classified as granulosa tumours (including granulosa cell tumours and theca-fibroma tumours), sertoli cell tumours, sex-cord tumours of mixed or unclassified cell types, gynandroblastoma and steroid cell tumours.

Germ cell tumours are classified as primitive germ cell tumours (including dysgerminoma, yolk sac tumour and embryonal carcinoma), biphasic or triphasic teratomas (including immature teratoma and mature teratoma), and monodermal teratoma (composed of a single type of tissue and includes struma ovarii, which is composed of thyroid cells).

Incidence and epidemiology

The annual incidence of ovarian cancer in the UK is 17 per 100,000 women, ranging from 14 per 100,000 in Northern Ireland to 20 per 100,000 in Wales. Approximately 7000 cases are reported per year in the UK.

Aghajanian, C., Blank, S., Goff, B., et al. (2012). OCEANS: a randomized, double-blind, placebo-controlled Phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer. J. Clin. Oncol., 30, 2039–2045.
Anonymous, . (1991). Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br. Med. J., 303, 884–893.
Anonymous, . (1998). ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer. Lancet, 352, 1571–1576.
Antoniou, A., Pharoah, P. D., Narod, S., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet., 72, 1117–1130.
Ayhan, A., Gultekin, M., Dursun, P., et al. (2008). Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance?Gynecol. Oncol., 108, 428–432.
Bookman, M., Brady, M., McGuire, W., et al. (2009). Evaluation of new-platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol., 27, 1419–1425.
Bower, M., Fife, K., Holden, L., et al. (1996). Chemotherapy for ovarian germ cell tumours. Eur. J. Cancer, 32A, 593–597.
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., et al. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol., 20, 1248–1259.
Burger, R., Brady, M., Brookman, M., et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New Engl. J. Med., 365, 2473–2483.
Callahan, M. J., Crum, C. P., Medeiros, F., et al. (2007). Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol., 25, 3985–3990.
Cantu, M., Buda, A., Parma, G., et al. (2002). Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J. Clin. Oncol., 20, 1232–1237.
Chan, J., Brady, M., Penson, R., et al. (2013). Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). Int. J. Gynecol. Cancer, 23 (8 suppl 1), 9–10.
Ferrandina, G., Ludovisi, M., Lorusso, D., et al. (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol., 26, 890–896.
Gordon, A. N., Tonda, M., Sun, S., et al. (2004). Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol., 95, 1–8.
Hanna, L. and Adams, M. (2006). Prevention of ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol., 20, 339–362.
Herzog, T. J. (2002). Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist, 7(Suppl. 5), 3–10.
ICON Group. (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomised trial. Lancet, 360, 505–515.
Kaern, J., Baekelandt, M. and Trope, C. (2002). A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. Eur. J. Gynaecol. Oncol., 23, 383–389.
Katsumata, N., Yasuda, M., Isonishi, S., et al. (2012). Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian rube or primary peritoneal cancer: JGOG 3016 trial. J. Clin. Oncol., 15 (Suppl.), abstract 5003.
Kehoe, S., Hook, J., Nankivell, N., et al. (2013). Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. J. Clin Oncol., 31(Suppl.), abstract 5500.
Kindelberger, D., Lee, Y., Miron, A., et al. (2007). Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol., 32, 161–169.
Kurman, R. and Shih, leM. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol., 34, 433–443.
Kyrgiou, M., Salanti, G., Pavlidis, N., et al. (2006). Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J. Natl Cancer Inst., 98, 1655–1663.
Ledermann, J., Harter, P., Gourley, G., et al. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol., 15, 852–861.
Liu, G., Yang, D., Sun, Y., et al. (2012). Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics, 13, 1523–1535.
Longacre, T. A., McKenney, J. K., Tazelaar, H. D., et al. (2005). Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or = 5-year) follow-up. Am. J. Surg. Pathol., 29, 707–723.
Lu, K. H., Dinh, M., Kohlmann, W., et al. (2005). Gynecologic cancer as a ‘sentinal cancer’ for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet. Gynecol., 105, 569–574.
Markman, M., Blessing, J., Rubin, S., et al. (2006). Phase II trial of weekly paclitaxel (80mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol., 101, 436–440.
McGuire, W. P., Hoskins, W. J., Brady, M. F., et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334, 1–6.
Meeuwissen, P. A., Seynaeve, C., Brekelmans, C. T., et al. (2005). Outcome of surveillance and prophylactic salpingooophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol. Oncol., 97, 476–482.
Menon, U., Gentry-Maharaj, A., Hallett, R., et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol., 10, 327–340.
Moran, B. J. and Cecil, T. D. (2003). The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg. Oncol. Clin. N. Am., 12, 585–603.
Muggia, F. and Hamilton, A. (2001). Phase II data on Caelyx® in ovarian cancer. Eur. J. Cancer, 37 (Suppl. 9), S15–18.
Muggia, F. M., Braly, P. S., Brady, M. F., et al. (2000). Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol., 18, 106–115.
Mutch, D., Orlando, M., Goss, T., et al. (2007). Randomized phase III trial of Gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol., 25, 2811–2818.
NICE. (2003). Technology Appraisal Guidance – No. 55. Guidance of the Use of Paclitaxel in the Treatment of Ovarian Cancer. London: National Institute for Clinical Excellence.
NICE. (2005). Technology Appraisal Guidance – No. 91. Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride and Topotecan for Second-line or Subsequent Treatment of Advanced Ovarian Cancer. Review of Technology Appraisal Guidance 28, 45 and 55. London: National Institute for Clinical Excellence.
NICE. (2011). Clinical Guideline 122; Ovarian Cancer – The Recognition and Initial Management of Ovarian Cancer.London: National Institute for Clinical Excellence.
NICE. (2013). Technology Appraisal Guidance – TA 284. Bevacizumab in Combination with Paclitaxel and Carboplatin for First-line Treatment of Advanced Ovarian Cancer. London: National Institute for Clinical Excellence.
Oza, A. M., Cook, A. D., Pfisterer, J., et al., (2015). Standard chemothrapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol., 16, 928–936.
Parmar, M. K., Ledermann, J. A., Colombo, N., et al. (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 361, 2099–2106.
Pfisterer, J., Plante, M., Vergote, I., et al. (2006). Gemcitabine and carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG and the EORTC GCG.J. Clin. Oncol., 24, 4699–4707.
Piccart, M. J., Bertelsen, K., James, K., et al. (2000a). Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst., 92, 699–708.
Piccart, M. J., Green, J., Lacave, L., et al. (2000b). Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer gynecology group. J. Clin. Oncol., 18, 1193–1202.
Pignata, S., Scambia, G., Katsaros, D., et al. (2014). Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO): a randomized, multicentre, open-label phase 3 trial. Lancet Oncol., 15, 396–405.
Poveda, A., Vergote, I., Tjulandin, S., et al. (2011). Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer in the partially-platinum sensitive sub-population of OVA-301 phase III randomised trial. Ann. Oncol., 22, 39–48.
Prat, J. (2013). Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynecol. Obstet.http://dx.doi.org/10.1016/j.ijgo.2013.10.001
Pujade-Lauraine, E., Hilpert, F., Weber, B., et al. (2014). Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol., 32, 1302–1308.
Risch, H. A., McLaughlin, J. R., Cole, D. E., et al. (2001). Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet., 68, 700–710.
Rose, P., Blessing, J., Mayer, A., et al. (1998). Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol., 16, 405–410.
Rosenthal, A., Fraser, L., Manchanda, R., et al. (2013). Results of annual screening in phase I of the United Kingdom Familial Ovarian Cancer Screening study highlight the need for strict adherence to screening schedule. J. Clin.Oncol., 31, 49–57.
Runowicz, C. (2006). Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery?Nat. Clin. Pract. Oncol., 3, 416–417.
Rustin, G., van der Burg, M., Griffin, C., et al. (2010). Early versus delayed treatment of relapsed ovarian cancer (MRC 0V05/EORTC 55955): a randomised trial. Lancet, 376, 1155–1163.
Sato, N., Tsunoda, H., Nishida, M., et al. (2000). Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res., 60, 7052–7056.
SIGN. (2003). Guideline 75. Epithelial Ovarian Cancer. Edinburgh: Scottish Intercollegiate Guidelines Network.
Struewing, J. P., Hartge, P., Wacholder, S., et al. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med., 336, 1401–1408.
ten Bokkel Huinink, W., Lane, S. and Ross, G. (2004). Long-term survival in a phase III randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann. Oncol., 15, 100–103.
Thigpen, J., Blessing, J., Ball, H., et al. (1994). Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology group study. J. Clin. Oncol. 12, 1748–1753.
Trimble, E., Adams, J., Vena, D., et al. (1993). Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center. J. Clin.Oncol., 11, 2405–2410.
Trimbos, J. B., Parmar, M., Vergote, I., et al. (2003). International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J. Natl Cancer. Inst., 95, 105–112.
Vergote, I., Tropé, C. G., Amant, F., et al. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med., 363, 943–953.
Wagner, U., Marth, C., Largillier, R., et al. (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br. J. Cancer, 107, 588–591.
Winter, E., Maxwell, L., Tian, C., et al. (2008). Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol., 26, 83–89.
WHO Classification. (2003). In World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs, ed. Tavassoli, A. and Devilee, P.. Lyon: IARC Press, Chapter 4.